Risk/benefit ratio of perioperative OKT3 in cardiac transplantation.
Transplant Proc
; 25(1 Pt 2): 1149-51, 1993 Feb.
Article
em En
| MEDLINE
| ID: mdl-8442068
ABSTRACT
This study shows that perioperative OKT3 provides no benefit in terms of the time of onset or frequency of rejection or patient survival. However, it does result in an increased incidence of infection, particularly CMV infection. Thus, the risk/benefit ratio of perioperative OKT3 does not appear favorable. However, a multicenter, randomized trial including a larger number of patients and longer patient follow-up will be required to definitively answer the question.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante de Coração
/
Muromonab-CD3
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1993
Tipo de documento:
Article